Losartan and Immune Checkpoint Inhibitors in Glioblastoma: An Appropriate Substitute for Steroids.
作者信息
Rangwala Burhanuddin Sohail, Shakil Areej, Mustafa Muhammad Saqlain, Rangwala Hussain Sohail, Fatima Hareer, Siddiq Mohammad Arham
机构信息
Department of Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan.
出版信息
Ann Neurosci. 2024 Jul;31(3):152-154. doi: 10.1177/09727531231191880. Epub 2023 Nov 3.
Abstract
摘要
相似文献
1
Losartan and Immune Checkpoint Inhibitors in Glioblastoma: An Appropriate Substitute for Steroids.
Ann Neurosci. 2024 Jul;31(3):152-154. doi: 10.1177/09727531231191880. Epub 2023 Nov 3.
2
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2219199120. doi: 10.1073/pnas.2219199120. Epub 2023 Feb 1.
3
Glucocorticoids and immune checkpoint inhibitors in glioblastoma.
J Neurooncol. 2021 Jan;151(1):13-20. doi: 10.1007/s11060-020-03439-2. Epub 2020 Feb 27.
4
Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.
Eur J Cancer. 2019 Mar;109:129-136. doi: 10.1016/j.ejca.2018.12.025. Epub 2019 Feb 1.
5
The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.
Neurosurg Clin N Am. 2021 Apr;32(2):235-248. doi: 10.1016/j.nec.2020.12.003.
6
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
J Pharmacol Exp Ther. 2023 Oct;387(1):66-77. doi: 10.1124/jpet.122.001571. Epub 2023 Jul 13.
7
The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review.
Neurooncol Adv. 2022 Jun 7;4(1):vdac087. doi: 10.1093/noajnl/vdac087. eCollection 2022 Jan-Dec.
8
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Front Immunol. 2020 Nov 30;11:592612. doi: 10.3389/fimmu.2020.592612. eCollection 2020.
9
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Int J Mol Sci. 2020 Apr 16;21(8):2759. doi: 10.3390/ijms21082759.
10
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
引用本文的文献
1
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
BMC Med. 2024 Dec 5;22(1):578. doi: 10.1186/s12916-024-03775-4.
2
Accuracy of MRI in Detecting 1p/19q Co-deletion Status of Gliomas: A Single-Center Retrospective Study.
Cureus. 2024 Jan 8;16(1):e51863. doi: 10.7759/cureus.51863. eCollection 2024 Jan.
本文引用的文献
1
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2219199120. doi: 10.1073/pnas.2219199120. Epub 2023 Feb 1.
2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Front Immunol. 2020 Nov 30;11:592612. doi: 10.3389/fimmu.2020.592612. eCollection 2020.
4
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16.
5
Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Cancer Biol Med. 2020 Aug 15;17(3):555-568. doi: 10.20892/j.issn.2095-3941.2020.0027.
6
Tumour-intrinsic resistance to immune checkpoint blockade.
Nat Rev Immunol. 2020 Jan;20(1):25-39. doi: 10.1038/s41577-019-0218-4. Epub 2019 Sep 30.
7
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3.
8
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
9
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Cancer Discov. 2018 Sep;8(9):1069-1086. doi: 10.1158/2159-8290.CD-18-0367. Epub 2018 Aug 16.
10
Epidemiology for primary brain tumors: a nationwide population-based study.
J Neurooncol. 2017 Feb;131(3):525-546. doi: 10.1007/s11060-016-2318-3. Epub 2016 Nov 16.
Zotero 插件